nvunehg

Property	Value
?:abstract	Background: Laboratory diagnosis of SARS-CoV-2 infection (the cause of COVID-19) uses PCR to detect viral RNA (vRNA) in respiratory samples. SARS-CoV-2 RNA has also been detected in other sample types, but there is limited understanding of the clinical or laboratory significance of its detection in blood. Methods: We undertook a systematic literature review to assimilate the evidence for the frequency of vRNA in blood, and to identify associated clinical characteristics. We performed RT-PCR in serum samples from a UK clinical cohort of acute and convalescent COVID-19 cases (n=212), together with convalescent plasma samples collected by NHS Blood and Transplant (NHSBT) (n=462 additional samples). To determine whether PCR-positive blood samples could pose an infection risk, we attempted virus isolation from a subset of RNA-positive samples. Results: We identified 28 relevant studies, reporting SARS-CoV-2 RNA in 0-76% of blood samples; pooled estimate 10% (95%CI 5-18%). Among serum samples from our clinical cohort, 27/212 (12.7%) had SARS-CoV-2 RNA detected by RT-PCR. RNA detection occurred in samples up to day 20 post symptom onset, and was associated with more severe disease (multivariable odds ratio 7.5). Across all samples collected ≥28 days post symptom onset, 0/494 (0%, 95%CI 0-0.7%) had vRNA detected. Among our PCR-positive samples, cycle threshold (ct) values were high (range 33.5-44.8), suggesting low vRNA copy numbers. PCR-positive sera inoculated into cell culture did not produce any cytopathic effect or yield an increase in detectable SARS-CoV-2 RNA. There was a relationship between RT-PCR negativity and the presence of total SARS-CoV-2 antibody (p=0.02). Conclusions: vRNA was detectable at low viral loads in a minority of serum samples collected in acute infection, but was not associated with infectious SARS-CoV-2 (within the limitations of the assays used). This work helps to inform biosafety precautions for handling blood products from patients with current or previous COVID-19.
is ?:annotates of	<https://research.tib.eu/covid-19/entity/6nvunehg_hasAnnotation_C0010827> <https://research.tib.eu/covid-19/entity/6nvunehg_hasAnnotation_C0035668> <https://research.tib.eu/covid-19/entity/6nvunehg_hasAnnotation_C0035736> <https://research.tib.eu/covid-19/entity/6nvunehg_hasAnnotation_C0042776> <https://research.tib.eu/covid-19/entity/6nvunehg_hasAnnotation_C0456388> <https://research.tib.eu/covid-19/entity/6nvunehg_hasAnnotation_C1417647> <https://research.tib.eu/covid-19/entity/6nvunehg_hasAnnotation_C5203676>
?:creator	<https://research.tib.eu/covid-19/entity/Andersson%2C_Monique_I%3B_Arancibia-Carcamo%2C_Carolina_V%3B_Auckland%2C_Kathryn%3B_Baillie%2C_J_Kenneth%3B_Barnes%2C_Eleanor%3B_Beneke%2C_Tom%3B_Bibi%2C_Sagida%3B_Brooks%2C_Tim%3B_Carroll%2C_Miles%3B_Crook%2C_Derrick%3B_Dingle%2C_Kate%3B_Dold%2C_Christina%3B_Downs%2C_Louise_O%3B_Dunn%2C_Laura%3B_Eyre%2C_David_W%3B_Gilbert_Jaramillo%2C_Javier%3B_Harvala%2C_Heli%3B_Hoosdally%2C_Sarah%3B_Ijaz%2C_Samreen%3B_James%2C_Tim%3B_James%2C_William%3B_Jeffery%2C_Katie%3B_Justice%2C_Anita%3B_Klenerman%2C_Paul%3B_Knight%2C_Julian_C%3B_Knight%2C_Michael%3B_Liu%2C_Xu%3B_Lumley%2C_Sheila_F%3B_Matthews%2C_Philippa_C%3B_McNaughton%2C_Anna_L%3B_Mentzer%2C_Alexander_J%3B_Mongkolsapaya%2C_Juthathip%3B_Oakley%2C_Sarah%3B_Oliveira%2C_Marta_S%3B_Peto%2C_Timothy%3B_Ploeg%2C_Rutger_J%3B_Ratcliff%2C_Jeremy%3B_Robbins%2C_Melanie_J%3B_Roberts%2C_David_J%3B_Rudkin%2C_Justine%3B_Russell%2C_Rebecca_A%3B_Screaton%2C_Gavin%3B_Semple%2C_Malcolm_G%3B_Skelly%2C_Donal%3B_Simmonds%2C_Peter%3B_Stoesser%2C_Nicole%3B_Turtle%2C_Lance%3B_Wareing%2C_Susan%3B_Zambon%2C_Maria>
?:journal	Wellcome_Open_Res
?:license	unk
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
is ?:relation_isRelatedTo_publication of	<https://research.tib.eu/covid-19/entity/6nvunehg_HAS_C5203676_COEXISTS_WITH_C5203670>
?:source	WHO
?:title	SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:who_covidence_id	#1024793 #963993
?:year	2020

Property

Value

?:abstract

Background: Laboratory diagnosis of SARS-CoV-2 infection (the cause of COVID-19) uses PCR to detect viral RNA (vRNA) in respiratory samples. SARS-CoV-2 RNA has also been detected in other sample types, but there is limited understanding of the clinical or laboratory significance of its detection in blood. Methods: We undertook a systematic literature review to assimilate the evidence for the frequency of vRNA in blood, and to identify associated clinical characteristics. We performed RT-PCR in serum samples from a UK clinical cohort of acute and convalescent COVID-19 cases (n=212), together with convalescent plasma samples collected by NHS Blood and Transplant (NHSBT) (n=462 additional samples). To determine whether PCR-positive blood samples could pose an infection risk, we attempted virus isolation from a subset of RNA-positive samples. Results: We identified 28 relevant studies, reporting SARS-CoV-2 RNA in 0-76% of blood samples; pooled estimate 10% (95%CI 5-18%). Among serum samples from our clinical cohort, 27/212 (12.7%) had SARS-CoV-2 RNA detected by RT-PCR. RNA detection occurred in samples up to day 20 post symptom onset, and was associated with more severe disease (multivariable odds ratio 7.5). Across all samples collected ≥28 days post symptom onset, 0/494 (0%, 95%CI 0-0.7%) had vRNA detected. Among our PCR-positive samples, cycle threshold (ct) values were high (range 33.5-44.8), suggesting low vRNA copy numbers. PCR-positive sera inoculated into cell culture did not produce any cytopathic effect or yield an increase in detectable SARS-CoV-2 RNA. There was a relationship between RT-PCR negativity and the presence of total SARS-CoV-2 antibody (p=0.02). Conclusions: vRNA was detectable at low viral loads in a minority of serum samples collected in acute infection, but was not associated with infectious SARS-CoV-2 (within the limitations of the assays used). This work helps to inform biosafety precautions for handling blood products from patients with current or previous COVID-19.

is ?:annotates of